Nexalis Therapeutics Begins First-in-Human Trial for Inhaled CBD Panic Therapy
Nexalis Therapeutics Ltd (ASX: NX1), formerly known as InhaleRx Limited, is an Australian clinical-stage biotechnology company headquartered in Melbourne, Victoria. Listed on the Australian Securities Exchange under the ticker NX1, the entity specializes in the research and development of unique medicinal drug-device products and novel oral formulations. Its primary business focus is the creation of rapid-onset therapies designed to address significant unmet medical needs within the global healthcare landscape, particularly in the fields of pain management and mental health.
The company’s operational portfolio features several key clinical programs, including IRX-211, an inhaled therapy targeting breakthrough cancer pain, and IRX-616a, which is being developed for the treatment of panic disorder. A major recent addition to its assets is SRX-25, a ketamine-based oral fixed-dose combination therapy specifically designed for patients suffering from treatment-resistant depression. This expansion into oral drug delivery represents a strategic shift for the company, allowing it to leverage a broader range of administration methods to improve patient outcomes and accessibility.
Nexalis Therapeutics maintains a strategic market position by targeting high-growth sectors in psychiatric medicine and oncology support. The company’s value proposition is built upon utilizing the U.S. FDA 505(b)(2) regulatory pathway, which offers a more rapid and cost-effective route to commercialization for differentiated drug candidates. By focusing on rapid-onset solutions and securing robust funding facilities, Nexalis aims to deliver scalable therapeutic options to clinicians and patients while maximizing shareholder value through the development of phase-3-ready pharmaceutical assets.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.